Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer

Genetic Vaccines and Therapy

Volumn 2, Issue , 2004, Pages

  Nagaraj, Srinivas ^a   Ziske, Carsten ^a   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

CIK; Dendritic cells; Gene therapy; IL 2

Indexed keywords

PLASMID DNA; RECOMBINANT INTERLEUKIN 2;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY TEST; DENDRITIC CELL; EFFECTOR CELL; ELECTRICAL PARAMETERS; ELECTROPORATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; KILLER CELL; MALIGNANT NEOPLASTIC DISEASE; NONVIRAL GENE DELIVERY SYSTEM; PANCREAS CARCINOMA; TARGET CELL; TUMOR CELL DESTRUCTION;

EID: 16344365608     PISSN: 14790556     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-0556-2-12     Document Type: Article

References (23)

1. Sobol RE, Shawler DL, Carson C, Van Beveren C, Mercola D, Fakhrai H, Garrett MA, Barone R, Goldfarb P, Bartholomew RM, et al. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: A Phase I study. Clin Cancer Res 1999, 5(9):2359-2365.
2. Lohr F, Lo DY, Zaharoff DA, Hu K, Zhang X, Li Y, Zhao Y, Dewhirst MW, Yuan F, Li CY: Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res 2001, 61(8):3281-3284.
3. Slos P, De Meyer M, Leroy P, Rousseau C, Acres B: Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: Induction of CD8(+) T-cell immunity and NK activity. Cancer Gene Ther 2001, 8(5): 21-332.
4. Schmidt-Wolf IGH, Negrin RS, Kiem HP, Blume KG, Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991, 174(1):139-149.
5. Lu PH, Negrin RS: A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994, 153(4):1687-1696.
6. Margolin KA, Negrin RS, Wong KK, Chatterjee S, Wright C, Forman SJ: Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev 1997, 157: 231-240.
7. Schmidt-Wolf IGH, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS: Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993, 21(13): 673-1679.
8. Schmidt-Wolf IGH, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, et al.: Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999, 81(6):1009-1016.
9. Amigorena S: Exosomes derived from dendritic cells. J Soc Biol 2001, 195(1):25-27.
10. Shurin MR: Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 1996, 43(3):158-164.
11. Marten A, Greten T, Ziske C, Renoth S, Schottker B, Buttgereit P, Schakowski F, von Rucker A, Sauerbruch T, Schmidt-Wolf IGH: Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cells. Cancer Immunol Immunother 2002, 51(1):25-32.
12. Glazyrin AL, Kan-Mitchell J, Mitchell ML: Analysis of in vitro immunization: Generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells. Cancer Immunol Immunother 2003, 52(3):171-178.
13. Blomberg K, Hautala R, Lovgren J, Mukkala VM, Lindqvist C, Akerman K: Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand. J Immunol Methods 1996, 193(2):199-206.
14. Marten A, Ziske C, Schottker B, Weineck S, Renoth S, Buttgereit P, Schakowski F, Konig S, von Rucker A, Allera A, et al.: Transfection of dendritic cells (DCs) with the CIITA gene: Increase in immunostimulatory activity of DCs. Cancer Gene Ther 2001, 8(3):211-219.
15. Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG: Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 1997, 74(2):51-56.
16. Marten A, Ziske C, Schottker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, von Rucker A, Sauerbruch T, Schmidt-Wolf IGH: Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother 2001, 24(6):502-510.
17. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987, 316(15): 889-897.
18. Tanaka M, Saijo Y, Sato G, Suzuki T, Tazawa R, Satoh K, Nukiwa T: Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma. Cancer Gene Ther 2000, 7(11):1481-1490.
19. Hwu P, Yannelli J, Kriegler M, Anderson WF, Perez C, Chiang Y, Schwarz S, Cowherd R, Delgado C, Mule J, et al.: Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. J Immunol 1993, 150(9):4104-4115.
20. Lode HN, Xiang R, Perri P, Pertl U, Lode A, Gillies SD, Reisfeld RA: What to do with targeted IL-2. Drugs Today (Barc 2000, 36(5):321-336.
21. Toomey JA, Gays F, Foster D, Brooks CG: Cytokine requirements for the growth and development of mouse NK cells in vitro. J Leukoc Biol 2003, 74(2):233-242.
22. Belldegrun A, Tso CL, Sakata T, Duckett T, Brunda MJ, Barsky SH, Chai J, Kaboo R, Lavey RS, McBride WH, et al.: Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): Implications for live cancer vaccines. J Natl Cancer Inst 1993, 85(3):207-216.
23. Daniels GA, Galanis E: Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/ DOPE lipid complex. Curr Opin Mol Ther 2001, 3(1):70-76.